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Abstract 
Background: Autoimmune diseases and schizophrenia share many common features. Association studies confirm 
a shared genetic association in the human leukocyte antigen (HLA) region between schizophrenia and most autoim‑
mune diseases. To our knowledge, the simultaneous syndromes of Graves’ disease (GD) and type 2 diabetes (T2D) in 
schizophrenia are rare in Tunisia.
Case presentation: We report a case of a 42‑year‑old woman admitted to the department of psychiatry for an acute 
relapse of chronic schizophrenia. Her medical history revealed that she was followed for Graves’ disease and for a type 
2 diabetes mellitus. A low‑resolution HLA typing was performed by polymerase chain reaction sequence‑specific 
primer (PCR‑SSP) techniques according to determine the patient’s haplotype.
Conclusions: Our study suggests that the HLA DRB1*03 allele may explain a common etiology underlying the co‑
morbidity of Graves’ disease, type 2 diabetes, and schizophrenia in our patient.
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Background
People with schizophrenia often develop somatic symp-
toms, particularly autoimmune disorders [1]. Previ-
ous studies have reported that, compared with the 
general population, individuals with schizophrenia have 
a different prevalence of some autoimmune diseases 
and experience different immunological responses [1, 
2]. Autoimmune involvement may have potential influ-
ence on central nervous system (CNS) pathologies which 
generates antibodies against the brain tissue in those 
with schizophrenia [3, 4]. A pathogenic theory of schizo-
phrenia posits its proximate cause to be an infection dur-
ing early development whereby antigens, similar to that 
found in CNS tissue, give rise to auto-antibodies that act 
against the brain.
Dopamine, which is inhibitory to TSH secretion, was 
found to be increased in schizophrenic patients. Sub-
sequent clinical evidence has also shown an excess of 
thyroid hormone dysfunction in schizophrenia that can 
result in cognitive function impairment with emotional 
and behavioral disturbances. Furthermore, other stud-
ies have revealed an association between Graves’ disease 
and schizophrenia. Some have attributed these manifold 
observations to dysfunction of the hypothalamus-pitui-
tary-thyroid axis [5–7].
Case presentation
A 42-year-old woman was admitted to the Department of 
Psychiatry of the Military Hospital of Tunis for an acute 
relapse of chronic schizophrenia. Her medical history 
revealed that the patient was followed for seven years 
for Graves’ disease treated by synthetic anti-thyroids and 
for a type 2 diabetes mellitus treated by metformin. The 
patient received antipsychotic therapy for three weeks 
during recovery in the Department of Psychiatry and is 
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now followed regularly for her associated diseases. The 
co-existence of those diseases has motivated a genetic 
analysis to seek a common syndromic pathology. The 
patient gave informed consent to giving a blood sample 
for genetic analysis. The study protocol was approved by 
the Ethics Committee of the Military Hospital of Tunisia 
and has therefore been performed in accordance with the 
ethical standards laid down in the 1964 Declaration of 
Helsinki and its later amendments.
HLA typing by DNA amplification
Genomic DNA was extracted from peripheral blood 
samples of patients and healthy individuals using the 
QIAamp DNA Blood Mini Kit (QIAGEN GmbH, Hilden, 
Germany). Low-resolution HLA typing was performed 
by polymerase chain reaction sequence-specific primer 
(PCR-SSP) techniques according to Micro SSP DNA 
Typing Trays DRB/DQB (One Lambda Inc. Canoga 
Park, California, USA). Amplified DNA fragments were 
detected by agarose gel electrophoresis (2.5% agarose 
gel), stained with ethidium bromide, and UV transillu-
mination. One Lambda DNA/LMT software version 3.98 
was used to detect specific DRB1 and DQB1 alleles.
Results
The genetic investigation revealed that the patient carried 
the HLA DRB1*03-HLA DQB1*02 haplotype. We sup-
pose that HLA DRB1*03 may be the common cause of 
these three simultaneous diseases.
Discussion
We report a case of a patient presenting co-occurrences 
of Graves’ disease, type 2 diabetes, and schizophrenia. 
The genetic investigation revealed that the patient car-
ried the DRB1*03-DQB1*02 haplotype. Many subsequent 
studies have noted similarities between schizophrenia 
and other autoimmune diseases [1]. Firstly, the diagnos-
tic procedures are largely dependent on clinical criteria 
such as the lack of a specific etiological diagnosis. Sec-
ondly, the treatments are usually palliative, not curative. 
Thirdly, both are complex disorders caused by multi-
ple genetic, environmental, and lifestyle factors, and the 
interaction between these factors do not follow a clear 
Mendelian pattern of inheritance. Furthermore, due to 
limited knowledge of pathophysiology, individuals with 
schizophrenia and/or certain autoimmune diseases may 
be similar in clinical presentation, but their underlying 
etiologies are very heterogeneous.
Recent genome-wide association studies have identi-
fied a growing number of disease-associated loci and 
have provided enormous insight into the etiology of com-
plex genetic disorders, including schizophrenia and auto-
immune diseases [8, 9].
Strikingly, consistent with the results from previous 
linkage and case–control association studies, genome-
wide association study results confirmed a shared genetic 
association in the human leukocyte antigen (HLA) region 
between schizophrenia and most autoimmune diseases. 
Caucasian patients with GD usually present the HLA-
DRB1*03 allele in strong linkage disequilibrium with 
the HLA-DQB1*0201 [10, 11]. Also, in native South 
Africans, HLA-DR1 has been associated with GD [12]. 
Moreover, very few studies examined a possible role for 
HLA class II in type 2 diabetes in relation to autoim-
mune markers and latent autoimmune diabetes in adults 
and association with complications of diabetes. This 
was exemplified by the findings that DQB1*0201 and 
DQB1*0302 [13], DRB1*03/04-DQB1*0302 [14, 15], and 
DRB1*03-DQA1*0502-DQB1*0201 (DR3-DQ2) were 
positively associated with type 2 diabetes [16]. Further-
more, the HLA-DRB1 gene has been a focus in investi-
gating the HLA association with schizophrenia [17]. A 
strong positive association between HLA-DRB1*03 and 
HLA DQB1*02 alleles and schizophrenia has widely been 
reported in the Saudi and Tunisian populations [18, 19].
Although associations between the HLA loci and GD, 
schizophrenia, and T2D are well established, the under-
lying mechanisms through which HLA molecules con-
fer susceptibility to those diseases simultaneously are 
still unclear. It is known that the major function of HLA 
class II molecules (DR, DQ, and DP), in the normal cel-
lular and humoral immune response, is to bind peptide 
antigens and present them to T cell receptors [20]. There 
is persuasive evidence that these diseases are associated 
with specific amino acid sequences of the DRB1 and DQ 
genes. It is thought that different HLA alleles have differ-
ent affinities for peptides from auto-antigens such as the 
TSH receptor, dopamine receptors, and GAD antibod-
ies. Knight postulates that the acute positive symptoms 
of schizophrenia are caused by auto-antibodies which 
interact with and stimulate dopamine receptors in cer-
tain neural pathways of the brain (dopamine-receptor-
stimulating auto-antibodies) [21]. Despite the failure 
of some studies to detect dopamine receptor auto-anti-
bodies in schizophrenia patients [22, 23], the hypothesis 
of a major role of dopamine receptor serum antibodies 
is further supported by recent findings of an increased 
production of pro-inflammatory cytokines and auto-
antibodies in acutely ill schizophrenia patients [24, 25]. 
These antibodies would be analogous to the thyroid-
stimulating auto-antibodies which cause the hyperthy-
roidism of Graves’ disease [21]. In the same way, GAD 
antibodies would also be analogous to both previously 
discussed antibodies. Thus, only specific HLA-DR alleles 
with the appropriate amino acids in its peptide-binding 
pocket would allow an auto-antigenic peptide to bind 
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and to be recognized by the T-cell receptor [26]. This 
will eventually lead to hyperthyroidism by overproduc-
tion of thyroid-stimulating auto-antibodies. Specifically, 
HLA-DRB1 may predispose to an autoimmune-mediated 
reduction in insulin secretory function, either by a loss of 
beta cell mass or interference with early insulin release 
[27, 28]. Although not all schizophrenic patients suffer 
from glucose dysfunction, recent evidence has indicated 
a propensity toward such an association. Schoepf et  al. 
[29] demonstrated that the prevalence of type 2 diabetes 
was increased in schizophrenia compared to hospitalized 
controls, while the findings of Perry et al. [30] suggests a 
potential link between pre-diabetic markers, in particu-
lar impaired glucose tolerance and insulin resistance, and 
first-episode psychosis.
Very few studies, to date, have examined the correla-
tion between the structure of the HLA-DRB1 polymor-
phism and GD, schizophrenia, and T2D. A few studies 
have shown that an arginine residue at position 74 of the 
HLA-DRB1 chain plays an important role in the genetic 
susceptibility to those diseases [31, 32]. Since most DR3 
subtypes contain DRb-Arg74 it was possible that the 
association of DRb-Arg74 with GD was merely a reflec-
tion of the association of DR3 with GD, schizophrenia, 
and T2D [31]. It is much more likely that the DR struc-
ture itself could explain some of the well-established DR3 
associations with these autoimmune diseases.
Conclusion
Our study suggests that the HLA DRB1*03 haplo-
type may explain a common etiology underlying the 
co-morbidity of Graves’ disease, type 2 diabetes, and 
schizophrenia.
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